Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.

Eur J Heart Fail · 2021 · PMC8359415 · PMID 32946151

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Pecavaptan fully counteracted the decrease in CO, whereas tolvaptan exhibited only a slight trend of improvement in the 100 and 300 μg/kg doses.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.